{
  "docId": "019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "docSlug": "213575480fcc7466657230c6a0d87626",
  "documentTitle": "23andMe | Investor Day Presentation Deck | 78 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 78,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The slide uses a three-part flow: market size (left), industry landscape (center), and 23andMe's proprietary identification method (right).",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-f0b8-737f-9ff6-e8b6f7a1e960/34",
  "deckHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "deckJsonHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960.json",
  "deckAnchorHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.26,
        "x": 0.71,
        "y": 0.21
      },
      "kind": "callout",
      "text": "23andMe's I/O signature identifies targets that are genetically-driven",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52af2f20-fb74-4983-86bc-8c653133c1e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "callout",
      "text": "Large I/O market with over $41B expected in 2021 sales",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a60adb6b-5fd2-4b7e-9066-5bb197f8f157",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.35,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Global Immuno-Oncology Drug Development Pipeline",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f7ade4b-f81f-4f86-9978-8533bfb79644",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.24,
        "x": 0.72,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Similarity classifier diagram with binary selection",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8134cae7-2844-4e1c-b6c2-77e249d157b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1 Source: Evaluate Pharma historical and forecast estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d379d80f-98d1-44af-a927-ed39a2a4271d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "table",
      "text": "KEYTRUDA $17.0B, OPDIVO $7.9B, YERVOY $1.8B",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94aa4fa0-ba35-46c2-bac3-5dc75ca037e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.78,
        "x": 0.11,
        "y": 0.05
      },
      "kind": "title",
      "text": "23andMe Immune-Oncology (I/O) Signature Highlights Genetically-Driven Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "841196d8-ded1-47d6-9b96-1bf4fdf252f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "8b30d2b6-4d35-4e19-a682-de9f442df637",
      "evidence": "The slide bridges the market opportunity (left) with the company's solution (right) via the industry context (center).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 33,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "934e5ad9-c4e2-4bad-8ae5-f1cb9185ca0d",
      "evidence": "The presentation deck presents data and research findings on 23ME-00610, a novel immuno-oncology antibody targeting CD200R1",
      "position": 1,
      "objective": "Can 23andMe's immuno-oncology antibody targeting CD200R1 provide a quick win in cancer treatment?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}